Raeth U, Johnson P J, Williams R
Liver. 1984 Oct;4(5):287-93. doi: 10.1111/j.1600-0676.1984.tb00940.x.
The value of ultrasound-measured liver volume in assessing response to therapy in patients with malignant liver disease was determined by the method originally described by Carr, which was modified and validated. Volumes measured in five cadavers by ultrasound and, after removal, by water displacement agreed to within 8% and the wide range of volumes in 20 normal subjects (800-2400 ml) was closely correlated with body weight. In 20 patients with non-malignant diffuse liver disease (cirrhosis or fatty liver) and 33 with malignant liver disease, initial volumes ranged from 1000 to 4900 ml and did not correlate with body weight. Changes in response to therapy in 15 patients with malignant liver disease were monitored by serial measurements with demonstrable changes in volume which, in those with alpha-fetoprotein tumours, were in parallel with changes in serum alpha-fetoprotein levels.
超声测量肝脏体积在评估恶性肝病患者治疗反应中的价值,采用最初由卡尔描述并经修改和验证的方法来确定。通过超声在五具尸体上测量的体积,与切除后通过水置换法测量的体积相差在8%以内,并且20名正常受试者(800 - 2400毫升)的广泛体积范围与体重密切相关。在20例非恶性弥漫性肝病(肝硬化或脂肪肝)患者和33例恶性肝病患者中,初始体积范围为1000至4900毫升,且与体重无关。通过连续测量对15例恶性肝病患者的治疗反应变化进行监测,体积有明显变化,在甲胎蛋白肿瘤患者中,这些变化与血清甲胎蛋白水平的变化平行。